These results suggest that at the time of diagnosis, drug-naive PD patients exhibit significantly increased PBMCs co-expressing dopaminergic markers DAT and TH, and that treatment for PD may modulate peripheral immune cells expressing dopaminergic machinery. This evidence concerns the gene SLC6A3 and Parkinson disease.